Nine investment firms moved together on Esperion as its losses narrowed and control shifted

What turned up

Nine selective investment institutions recently moved in the same direction on Esperion Therapeutics, Inc. (ESPR). No routine mechanical explanation, such as an index rebalancing, turned up in the filings to explain why all nine acted together, though public disclosures alone cannot prove their motives. Esperion is a pharmaceutical company that develops and sells once-daily, non-statin pills to lower elevated cholesterol. A look through its recent annual reports shows a business that has grown its sales fivefold over five years while heavily diluting existing shareholders and culminating in a July 2026 change of control.

What the numbers say

The figures below come directly from Esperion's audited annual reports for 2021 through 2025, rounded to the nearest tenth of a billion dollars (except share count, which is in millions).

Metric	2021	2022	2023	2024	2025
Revenue	$0.1B	$0.1B	$0.1B	$0.3B	$0.4B
Net income (loss)	-$0.3B	-$0.2B	-$0.2B	-$0.1B	$0.0B
Operating cash flow	-$0.3B	-$0.2B	-$0.1B	$0.0B	$0.0B
Cash	$0.2B	$0.1B	$0.1B	$0.1B	$0.2B
Shareholders' equity	-$0.2B	-$0.3B	-$0.5B	-$0.4B	-$0.3B
Diluted share count	29M	66M	103M	187M	208M

Behind the rounded table, exact reported revenue climbed from $0.08 billion in 2022 and $0.12 billion in 2023 to $0.33 billion in 2024 (a 185.7% jump) and $0.40 billion in 2025 (up another 21.3%), while the annual net loss shrank from $0.27 billion in 2021 to $0.02 billion in 2025 and operating cash burn narrowed from $0.26 billion to $0.01 billion. Notably, receivables—money owed by customers for product already recorded as sold—grew 65.3% in 2024 and 74.9% in 2025, outpacing revenue growth in the latter year. Over that same five-year stretch, the company kept its cash balance between $0.08 billion and $0.21 billion partly by issuing stock: the diluted share count expanded More than sevenfold from 29 million to 208 million, meaning a single share in 2025 represented less than one-seventh of the ownership slice it held in 2021.

What the company has been doing

Esperion filed 25 event reports over the past two years, showing constant activity in the boardroom and repeated financial restructuring. In December 2024, the company signed major agreements and took on new financial obligations twice within a single week. Between April and November 2025, management and board turnover became a regular feature, with five separate filings reporting changes to directors or senior officers alongside another major agreement in October 2025. The pace accelerated in the spring of 2026: Esperion signed major agreements in March, April, and May, with the April 2026 event also completing an acquisition or asset disposal and taking on another financial obligation. After one more officer or director change in June 2026, everything came to a head on July 13, 2026. On that single day, the company filed a report disclosing that it had signed a new agreement, terminated an old one, completed an acquisition or disposal, taken on a financial obligation, received a stock-exchange listing notice, overhauled its leadership and charter, and undergone a formal change in control.

What changed in the fine print

Comparing the company's annual reports shows management shifting its legal disclosures away from clinical trial milestones and toward detailed commercial and medical risks. Between the 2023 and 2024 reports, Esperion added 175 warning passages and dropped 102, retiring language about "seeking to add the use of both NEXLETOL and NEXLIZET for cardiovascular risk reduction" once those regulatory filings were behind it. In their place, management added broad cautions about its market size numbers, noting that "no independent source has verified such assumptions." Between the 2024 and 2025 reports, another 147 warnings were added and 87 were dropped, removing background descriptions of its completed CLEAR Outcomes cardiovascular trial and a Phase 3 trial in Japan. Instead, the 2025 annual report introduced specific clinical language regarding side effects and patient conditions, stating that "the risk of hyperuricemia and/or gout related to bempedoic acid use appeared to be attenuated by using uric acid lowering medications" and highlighting severe vascular risks such as "deep vein thrombosis and pulmonary embolism" or "amputations" in patients with diabetes and peripheral artery disease.

How the market has taken it

Between September 18, 2025, and July 13, 2026, Esperion's stock price rose 15.6% overall, finishing that span at $3.18 per share, though daily reactions to company filings were volatile. When Esperion announced a major agreement on March 3, 2026, and filed its 2025 annual report a week later on March 10, trading volume ran just over twice its 60-day average and the stock dropped 11.0% and 11.2% on those respective days. By contrast, when the company filed another major agreement on May 1, 2026, trading volume exploded to 32.2 times normal levels and the shares jumped 55.5% in a single session. Subsequent governance and shareholder-vote filings in June and early July 2026 drew between 2.2 and 6.4 times normal volume but moved the stock by less than 1% either way.

What this doesn't tell you

• Why the nine institutions agreed: While no routine mechanical trigger explains why nine selective firms moved the same way, filings only record what they did with their shares, not their internal reasoning or whether they were reacting to the May agreement or July change of control.
• The terms of the July 2026 upheaval: Event logs show that Esperion changed control, received a listing notice, and took on financial obligations on July 13, 2026, but the summary categories do not reveal the exact dollar terms or who now controls the company.
• Total debt load: Standard long-term debt figures were not broken out in the five-year summary table, even though the company repeatedly reported taking on material financial obligations and carried negative shareholders' equity (meaning total liabilities exceeded total assets by $0.30 billion at the end of 2025).
• Why customer IOUs grew so fast: Receivables grew by 74.9% in 2025 while revenue grew 21.3%, and the summary numbers alone do not explain whether customers are taking longer to pay or if sales were heavily weighted toward the very end of the year.